natgillin/translations-raw huggingface dataset:
• udsætte fostret for: - Kardiopulmonal toksicitet (med præmatur lukning af ductus arteriosus og pulmonal hypertension); - Renal dysfunktion, der kan udvikle sig til nyresvigt med oligo-hydroamniose; 
From the beginning of the sixth month of pregnancy, all prostaglandin synthesis inhibitors may expose: the foetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;
HDPE tabletbeholdere med hvide, gennemsigtige skruelåg af polypropylen med påsat aluminiumsforseglingsindlæg i kartonæsker, der indeholder 100 filmovertrukne tabletter. 
HDPE bottles with white opaque polypropylene screw cap with aluminium induction sealing liner wad and desiccant containing 100 film-coated tablets.
Acetylsalicylsyre hæmmer trombocytaggregation ved irreversibel hæmning af prostaglandincyklooxygenase og hæmmer derved dannelsen af tromboxan A2, en inducer af trombocytaggregation og vasokonstriktion. 
Acetylsalicylic acid inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclooxygenase and thus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction.
Patienterne fik clopidogrel (75 mg/dag, n = 22.961) plus ASA (162 mg/dag) eller ASA alene (162 mg/dag) (n = 22.891) i 28 dage eller indtil udskrivelse fra hospitalet. 
Patients received clopidogrel (75 mg/day, n=22,961) plus ASA (162 mg/day), or ASA alone (162 mg/day) (n=22,891), for 28 days or until hospital discharge.
Øjenblødning (konjunktival, okulær, retinal) 
Eye bleeding (conjunctival, ocular, retinal)
Patienter skal vejledes vedrørende risikoen for skader og blødning i mave-tarm-kanalen, hvis de drikker alkohol under behandlingen med clopidogrel plus ASA, især hvis alkoholforbruget er kronisk eller stort. 
Patients should be counselled about the risks of gastrointestinal injury and bleeding while taking clopidogrel plus ASA with alcohol, especially if alcohol consumption is chronic or heavy.
Ved midlertidig seponering af trombocythæmmende behandling bør Clopidogrel/Acetylsalicylic acid Mylan seponeres 7 dage før kirurgisk indgreb. 
If patients must temporarily stop antiplatelet therapy, Clopidogrel/Acetylsalicylic acid Mylan should be discontinued 7 days prior to surgery.
Clopidogrel/Acetylsalicylic acid Mylan er et fast-dosis- kombinationspræparat til fortsat behandling ved: 
Clopidogrel/Acetylsalicylic acid Mylan is a fixed-dose combination medicinal product for continuation of therapy in:
Brug af anden medicin sammen med Clopidogrel/Acetylsalicylic acid Mylan Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nyligt. 
Other medicines and Clopidogrel/Acetylsalicylic acid Mylan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Blødning i luftvejene (hæmoptyse, pulmonal blødning), bronkospasmer, interstitiel pneumoni, ikkekardiogent lungeødem ved kronisk brug eller i forbindelse med en overfølsomhedsreaktion på grund af acetylsalicylsyre eosinofil pneumoni. 
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, noncardiogenic pulmonary oedema with chronic use and in the context of a hypersensitivity reaction due to acetylsalicylic acid*, eosinophilic pneumonia.
• hvis du har aktiv blødning såsom et mavesår eller blødning i hjernen. 
• if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain.
Hjælpestoffer, som behandleren skal være opmærksom på Hver filmovertrukket tablet indeholder 48 mg lactose 
Excipients with known effect Each film-coated tablet contains 48 mg of lactose.
Der er kun begrænset erfaring med behandling af patienter med let til moderat nedsat nyrefunktion (se pkt. 
Therapeutic experience is limited in patients with mild to moderate renal impairment (see section 4.4).
Methotrexatdoser over 20 mg ugentligt bør anvendes med forsigtighed sammen med Clopidogrel/Acetylsalicylic acid Mylan, da ASA kan hæmme den renale clearance af methotrexat, hvilket kan føre til knoglemarvstoksicitet. 
Due to the presence of ASA, methotrexate used at doses higher than 20 mg/week should be used with caution with Clopidogrel/Acetylsalicylic acid Mylan as it can inhibit renal clearance of methotrexate, which may lead to bone marrow toxicity.
Den almindeligste bivirkning, der er set med Clopidogrel/Acetylsalicylic acid Mylan, er blødning. 
The most common side effect which has been seen with Clopidogrel/Acetylsalicylic acid Mylan is bleeding.
Non-steroide antiinflammatoriske stoffer (NSAID'er) I et klinisk studie foretaget med raske forsøgspersoner øgede samtidig administration af clopidogrel og naproxen okkult gastrointestinalt blodtab. 
In a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
Respiratoriske lidelser, lidelser i thorax og mediastinum 
Respiratory, thoracic and mediastinal disorders
• hvis du lider af en alvorlig nyresygdom. 
• if you suffer from severe kidney disease.
Blå mærker Udslæt, kløe, hudblødning (purpura) 
Rash, pruritus, skin bleeding (purpura)
I CAPRIE var den generelle forekomst af blødning 9,3 % hos patienter behandlet med enten clopidogrel eller ASA. 
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge eller apotekspersonalet til råds, før du tager Clopidogrel/Acetylsalicylic acid Mylan. 
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel/Acetylsalicylic acid Mylan.
Antallet af patienter, som oplevede det primære sammensatte endepunkt [kardiovaskulær død, myokardieinfarkt, apopleksi eller refraktær iskæmi] var 1.035 (16,5 %) i clopidogrel plus ASAgruppen og 1.187 (18,8 %) i ASA-gruppen, hvilket giver en relativ risikoreduktion på 14 % (95 % CI: 6 %-21 %; p = 0,00005) for clopidogrel plus ASA-gruppen. 
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel plus ASA group and 1,187 (18.8%) in the ASA group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel plus ASA group.
Mavesår og duodenalt ulcus, gastritis, opkastning, kvalme, obstipation, flatulens 
Gastric ulcer and duodenal ulcer, gastritis, vomiting, nausea, constipation, flatulence
Sikkerheden ved samtidig administration af clopidogrel/acetylsalicylsyre og andre trombolytika er ikke fastlagt, og der skal derfor udvises forsigtighed (se pkt. 
The safety of the concomitant administration of clopidogrel/acetylsalicylic acid with other thrombolytic agents has not been formally established and should be undertaken with caution (see section 4.4).
Samtidig administration af Clopidogrel/Acetylsalicylic acid Mylan og orale antikoagulantia kan ikke anbefales, da det kan øge blødningsintensiteten (se pkt. 
The concomitant administration of Clopidogrel/Acetylsalicylic acid Mylan with oral anticoagulants is not recommended since it may increase the intensity of bleeding (see section 4.4).
• hvis du lider af en nyre- eller leversygdom. 
• if you have kidney or liver disease.
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. 
If you get any side effects, talk to your doctor, or pharmacist.
Tabletkernen: 
Tablet core
Erfaring med behandling af patienter med moderat alvorlige leversygdomme, hvor der kan være disposition for blødning, er begrænset (se pkt. 
Therapeutic experience is limited in patients with moderate hepatic disease who may have bleeding diatheses (see section 4.4).
Lidelser i det centrale og perifere nervesystem 
Nervous system disorders
Gastrointestin al blødning, diaré, mavesmerter, dyspepsi 
Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia
Øvrige indholdsstoffer: - Tabletkernen: Mikrokrystallinsk cellulose, lactose (se afsnit 2 'Clopidogrel/Acetylsalicylic acid Mylan indeholder lactose'), croscarmellosenatrium, hydroxypropylcellulose, kolloid vandfri silica, talkum, hydrogeneret ricinusolie, pregelatineret stivelse, stearinsyre, gul jernoxid (E172). 
Tablet core: microcrystalline cellulose, lactose (see section 2 ‘Clopidogrel/Acetylsalicylic acid Mylan contains lactose'), croscarmellose sodium, hydroxypropylcellulose, colloidal anhydrous silica, talc, hydrogenated castor oil, pregelatinized starch, stearic acid, iron oxide yellow (E172).
- Filmovertræk: Hypromellose, triacetin, talkum, polyvinylalkohol (delvist hydrolyseret), titandioxid (E171), glycerol monocaprylocaprat (E422), natriumlaurilsulfat, gul jernoxid (E172) 
Tablet coating: hypromellose, triacetin, talc, poly (vinyl alcohol) (partially hydrolysed), titanium dioxide (E171), glycerol monocaprylocaprate (E422), sodium lauril sulfate, iron oxide yellow (E172)
Clopidogrel/Acetylsalicylic acid Mylan indeholder lactose. 
Clopidogrel/Acetylsalicylic acid Mylan contains lactose.
Som forholdsregel bør amning ophøre under behandling med Clopidogrel/Acetylsalicylic acid Mylan. 
Breast-feeding should be discontinued during treatment with Clopidogrel/Acetylsalicylic acid Mylan.
Virkning og anvendelse af Clopidogrel/Acetylsalicylic acid Mylan Det skal du vide, før du begynder at tage Clopidogrel/Acetylsalicylic acid Mylan Sådan skal du tage Clopidogrel/Acetylsalicylic acid Mylan Bivirkninger 
What Clopidogrel/Acetylsalicylic acid Mylan is and what it is used for What you need to know before you take Clopidogrel/Acetylsalicylic acid Mylan How to take Clopidogrel/Acetylsalicylic acid Mylan Possible side effects
Farmakoterapeutisk klassifikation: klassifikation: ATC-kode: Antitrombotiske midler blodpladeaggregationshæmmere ekskl. 
Pharmacotherapeutic group: group: ATC code: Antithrombotic agents, platelet aggregation inhibitors excl. Heparin, ATC Code: B01AC30.
Patienterne blev randomiseret til clopidogrel (300 mg initial støddosis efterfulgt af 75 mg/dag, N = 6.259) plus ASA (75-325 mg en gang daglig) eller ASA alene (N = 6.303), (75325 mg en gang daglig) i kombination anden standardbehandling. 
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) plus ASA (75-325 mg once daily) or ASA alone (N=6,303), (75-325 mg once daily) and other standard therapies.
Patienter skal vejledes vedrørende risikoen for skader og blødning i mave-tarm-kanalen, hvis de drikker alkohol under behandlingen med clopidogrel plus ASA, især hvis alkoholforbruget er kronisk eller stort (se pkt. 
Patients should be counselled about the risks of gastrointestinal injury and bleeding while taking clopidogrel plus ASA with alcohol, especially if alcohol consumption is chronic or heavy (see section 4.4).
Patienterne fik clopidogrel (300 mg støddosis efterfulgt af 75 mg daglig, n = 1.752) plus ASA eller ASA alene (n = 1.739) (150-325 mg som støddosis, herefter 75-162 mg daglig), et fibrinolytisk middel samt - når det var hensigtsmæssigt - heparin. 
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) plus ASA or ASA alone (n=1,739), (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Hospitalsindlæggelse er nødvendig ved indtagelse af toksisk dosis. 
If a toxic dose has been ingested then admission to hospital is necessary.
Til oral anvendelse. 
Method of administration For oral use.
Feber, ødem 
Fever, oedema*
Blisterkort af aluminium med et lag af tørremiddel i kartonæsker, der indeholder 28 eller 30 filmovertrukne tabletter. 
Aluminium blisters with desiccant layer containing 28 or 30 film-coated tablets.
Er du i tvivl, så spørg lægen eller apotekspersonalet. 
If you have any further questions, ask your doctor, or pharmacist.
- Filmovertræk: Hypromellose, triacetin, talkum, polyvinylalkohol (delvist hydrolyseret), titandioxid (E171), glycerol monocaprylocaprat (E422), natriumlaurilsulfat, Allura Red AC (E129) (se afsnit 2 'Clopidogrel/Acetylsalicylic acid Mylan indeholder Allura Red AC) Udseende og pakningsstørrelser for Clopidogrel/Acetylsalicylic acid Mylan 
Tablet coating: hypromellose, triacetin, talc, poly (vinyl alcohol) (partially hydrolysed), titanium dioxide (E171), glycerol monocaprylocaprate (E422), sodium lauril sulfate, Allura Red AC (E129) (see section 2 ‘Clopidogrel/Acetylsalicylic acid Mylan contains Allura Red AC')
Akut leversvigt, leverskader, primært hepatocellulær hepatitis, forhøjede leverenzymer 
Acute liver failure, liver injury, mainly hepatocellular*, hepatitis, elevation of hepatic enzymes*, abnormal liver function test, chronic hepatitis*
I litteraturen er der kun få tilgængelige data, der tillader en vurdering af det kliniske udbytte af CYP2C19-genotypebestemmelse i asiatiske befolkningsgrupper. 
From literature, limited data in Asian populations are available to assess the clinical implication of genotyping of this CYP on clinical outcome events.
I overensstemmelse med resultaterne ovenfor, blev det vist i en metaanalyse af 6 studier med 335 clopidogrelbehandlede ved steady state, at eksponeringen for den aktive metabolit nedsattes med 28 % for personer med moderat metabolisme, og 72 % for personer med ringe metabolisme. 
Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers.
Clopidogrel/Acetylsalicylic acid Mylan skal anvendes med forsigtighed til patienter i samtidig behandling med glykoprotein IIb/IIIa-hæmmere (se pkt. 
Clopidogrel/Acetylsalicylic acid Mylan should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
- heparin eller anden medicin til indsprøjtning til at nedsætte dannelse af blodpropper, - ticlopidin, eller anden medicin mod blodpropper, - selektive serotoningenoptagelseshæmmere (inklusive, men ikke begrænset til fluoxetin og fluvoxamin), der normalt anvendes mod depression, 
oral anticoagulants, medicines used to reduce blood clotting, ASA or another non-steroidal anti-inflammatory medicine usually used to treat painful and/or inflammatory conditions of muscle or joints, heparin or any other injectable medicine used to reduce blood clotting, ticlopidine, other antiplatelet agents, a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression,
Du skal holde op med at tage andre lægemidler, der indeholder clopidogrel, mens du tager Clopidogrel/Acetylsalicylic acid Mylan. 
You should stop other clopidogrel treatment while you are taking Clopidogrel/Acetylsalicylic acid Mylan.
Perforerede, enhedsdosis-blisterkort af aluminium med et lag af tørremiddel i kartonæsker, der indeholder 28 eller 30 filmovertrukne tabletter. 
Aluminium perforated unit dose blisters with desiccant layer containing 28 or 30 film-coated tablets.
Antallet af patienter, som oplevede det primære endepunkt [kardiovaskulær død (CV), myokardieinfarkt (MI) eller apopleksi] var 582 (9,3 %) i clopidogrel plus ASA-gruppen og 719 (11,4 %) i ASA-gruppen, hvilket giver en relativ risikoreduktion på 20 % (95 % CI: 10 %-28 %; p = 0,00009) for clopidogrel plus ASA-gruppen (en relativ risikoreduktion (RR) på 17 %, når patienterne fik konservativ behandling, 29 %, når de fik ballonudvidelse (perkutan transluminal koronar angioplastik (PTCA)) med eller uden stent, og 10 %, når de fik koronar bypassoperation (CABG). 
ASA group, a 20% relative risk reduction (RRR) (95% CI of 10%-28%; p=0.00009) for the clopidogrel plus ASA group [17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)].
Da Clopidogrel/Acetylsalicylic acid Mylan indeholder ASA, er det kontraindiceret i graviditetens tredje trimester. 
Due to the presence of ASA, Clopidogrel/Acetylsalicylic acid Mylan is contraindicated during the third trimester of pregnancy.
Det er usandsynligt, at Clopidogrel/Acetylsalicylic acid Mylan vil påvirke din evne til at køre bil eller betjene maskiner. 
Driving and using machines Clopidogrel/Acetylsalicylic acid Mylan should not affect your ability to drive or to use machines.
Efter gentagen dosering med clopidogrel 75 mg daglig var hæmningen af ADP-induceret trombocytaggregation lavere (25 %) hos forsøgspersoner med alvorlig nyresygdom (kreatininclearance 5-15 ml/min) end den, der blev set hos raske forsøgspersoner. 
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Der foreligger ingen data fra anvendelse af clopidogrel/acetylsalicylsyre til gravide kvinder. 
No clinical data on exposure to clopidogrel/acetylsalicylic acid during pregnancy are available.
Det vides ikke, om ASA-dosen i Clopidogrel/Acetylsalicylic acid Mylan påvirker fertiliteten. 
It is unknown whether ASA dose in Clopidogrel/Acetylsalicylic acid Mylan alters fertility.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg filmovertrukne tabletter indeholder Allura Red AC, hvilket kan forårsage allergiske reaktioner. 
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets contain Allura Red AC which may cause allergic reactions.
Samtidig administration af metamizol kan reducere den trombocytaggregerende effekt af ASA. 
Metamizole may reduce the effect of ASA on platelet aggregation when taken concomitantly.
Generelle symptomer og forstyrrelser ved applikationssted 
General disorders and administration site conditions
, insulin autoimmun syndrom, som kan føre til alvorlig hypoglykæmi, især hos patienter med HLA DRA4 subtype (hyppigere i den japanske befolkning) forværring af symptomer på fødeallergi 
Anaphylactic shock*, serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4) **, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population), aggravation of allergic symptoms of food allergy*
Dyrestudier har ikke vist, at clopidogrel påvirker fertiliteten. 
Clopidogrel was not shown to alter fertility in animal studies.
*, agranulocytose, alvorlig trombocytopeni, erhvervet hæmofili A, granulocytopeni, anæmi, hæmolytisk anæmi hos patienter med glucose-6-phosphatdehydrogen ase (G6PD)-mangel 
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section
Muskuloskeletale, bindevævs-og knoglelidelser 
Musculoskeletal and connective tissue disorders
Tabletbeholder 100 filmovertrukne tabletter 
Bottles 100 film-coated tablets
Dyreforsøg har påvist reproduktionstoksitet efter administration af en prostaglandinsyntesehæmmer (se pkt. 
In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in reproductive toxicity (see section 5.3).
Clopidogrel/Acetylsalicylic acid Mylan må ikke anvendes hos patienter med stærkt nedsat leverfunktion (se pkt. 
Clopidogrel/Acetylsalicylic acid Mylan must not be used in patients with severe renal impairment (see section 4.3).
Gastrointestinale (GI) bivirkninger omfatter mavesmerter, halsbrand, kvalme, opkastning og gastrointestinal blødning kan forekomme. 
GI undesirable effects including stomach pain, heartburn, nausea, vomiting, and GI bleeding may occur.
Trombotisk trombocytopenisk purpura (TTP) (se afsnit 4.4), knoglemarvssvigt 
Hypoglycaemia*, gout* (see section 4.4)
Opbevaring af Clopidogrel/Acetylsalicylic acid Mylan Pakningsstørrelser og yderligere oplysninger 
How to store Clopidogrel/Acetylsalicylic acid Mylan Contents of the pack and other information
Rapporteret i publiceret information for ASA med frekvens ”ikke kendt”. 
Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information reported in published information for ASA with frequency “not known”.
Gentagne doser af 75 mg clopidogrel/dag hæmmede i væsentlig grad den ADP-inducerede trombocytaggregation fra den første dag. 
Repeated doses of clopidogrel 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7.
Hvis acetylsalicylsyre anvendes af en kvinde der forsøger at blive gravid, eller indtil den 24. uge med amenorré (graviditetens 5. måned), bør dosis holdes så lav som muligt, og behandlingsvarigheden så kort som muligt. 
th month of pregnancy), the dose should be kept as low and duration of treatment as short as possible.
Tabletbeholderne indeholder et tørremiddel. 
The bottles contain a desiccant.
Hvad Clopidogrel/Acetylsalicylic acid Mylan indeholder 
What Clopidogrel/Acetylsalicylic acid Mylan contains
Syrepumpehæmmere (PPI) 
Proton Pump Inhibitors (PPI)
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg filmovertrukne tabletter Clopidogrel/Acetylsalicylic acid Mylan bør gives som en enkelt daglig dosis på 75 mg/75 mg. 
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Mylan should be given as a single daily 75 mg/75 mg dose.
Acetylsalicylsyre må ikke gives indtil den 24. uge med amenorré (graviditetens 5. måned), medmindre det er absolut nødvendigt. 
th month of pregnancy), acetylsalicylic acid should not be given unless clearly necessary.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 75 mg clopidogrel (som hydrogensulfat) og 75 mg acetylsalicylsyre (ASA). 
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid (ASA).
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 75 mg clopidogrel (som hydrogensulfat) og 100 mg acetylsalicylsyre (ASA). 
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid (ASA).
• Skal du fortælle lægen, at du er i behandling med Clopidogrel/Acetylsalicylic acid Mylan: - Hvis du skal have foretaget en planlagt operation (også hos tandlægen). 
• You should tell your doctor if a surgery (including dental) is planned.
*, unormal leverfunktionstest, kronisk hepatitis 
• Severe hepatic impairment.
• hvis du lider af urinsur gigt. 
• if you have gout.
Når du tager Clopidogrel/Acetylsalicylic acid Mylan 
While you are taking Clopidogrel/Acetylsalicylic acid Mylan
PRODUKTRESUME 
Manufacturers
Valproinsyre 
Valproic acid
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg filmovertrukne tabletter Pink, ovalformede, bikonvekse, filmovertrukne tabletter, ca. 14,8 mm × 7,8 mm, præget med et ”CA3” på den ene side af tabletten og et ”M” præget på den anden side. 
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets Pink, oval shaped, biconvex, film-coated tablets, approximately 14.8 mm x 7.8 mm debossed with “CA3” on one side of the tablet and “M” on the other side.